Douglas Tsao, an analyst from H.C. Wainwright, maintained the Buy rating on Xenon (XENE – Research Report) with a price target of $53.00. This rating is based on the promising results from Xenon’s ongoing trials and the positive reception of their new antiepileptic drug, azetukalner. The durable efficacy of azetukalner was highlighted at the recent American Epilepsy Society Meeting, particularly through the three-year data from the X-TOLE trial’s open-label extension, which showed significant reductions in seizure frequency and high retention rates.
The drug’s favorable tolerability and its positive impact on patients’ emotional well-being distinguish it from existing treatments, which often exacerbate psychiatric conditions. These aspects, along with the encouraging preclinical data from Xenon’s Dravet program, reinforce confidence in the company’s future prospects, justifying the Buy rating with a price target of $53.00.
Xenon Pharmaceuticals, Inc. engages in discovering and developing therapeutics to improve the lives of patients with neurological disorders. It focuses on the treatment of epilepsy. Its products include XEN496, XEN1101, XEN901, and XEN007. The company was founded by Simon Neil Pimstone, Johannes J. P. Kastelein, and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.
